Results 81 to 90 of about 5,674 (178)

Conformational Trajectory of the Molecular Chameleon Grazoprevir From Formulation to Target‐Bound

Chemistry – A European Journal, Volume 32, Issue 8, 23 February 2026.
ABSTRACT Macrocycles represent a promising class of beyond‐rule‐of‐5 (bRo5) therapeutics, capable of targeting proteins traditionally considered undruggable by conventional small molecules. Macrocycles exhibit intrinsic flexibility and often display a “chameleon‐like” ability to adapt to their environment, thereby enhancing their oral bioavailability ...
Lianne H. E. Wieske, Guanhong Bu, Máté Erdélyi, Jan Kihlberg, Tamir Gonen, Emma Rova Danelius   +5 more
wiley   +1 more source

RAS in NS3 and NS5A regions after failure of daclatasvir/asenaprevir combination therapy.

, 2016
RAS in NS3 and NS5A regions after failure of daclatasvir/asenaprevir combination therapy.
Miyako Murakawa (3239484), Takehiko Abe (3239505), Jun Itakura (554845), Shinya Sakita (3239508), Yasushi Ide (3239511), Masayuki Kurosaki (156560), Kouji Joko (3239496), Takashi Satou (3239469), Chikara Ogawa (3239478), Namiki Izumi (156627), Keiji Tsuji (3239502), Haruhiko Kobashi (3239490), Nobuyuki Enomoto (92837), Syotaro Tsuruta (3239475), Akeri Mitsuda (3239472), Yukio Osaki (170808), Kouichi Takaguchi (3239481), Hiroaki Okushin (3239499), Takashi Tamada (204139), Hiroyuki Hisai (3239493), Chitomi Hasebe (3239487), Hitoshi Yagisawa (147721), Yasuhiro Asahina (156563)   +22 more
core   +1 more source

Efficacy and safety of daclatasvir-containing regimens in the treatment of chronic hepatitis C patients in Damietta

Al-Azhar Assiut Medical Journal, 2020
Background Chronic hepatitis C virus infection is one of the most important health problems in Egypt. Since November 2015, generic sofosbuvir (SOF) with daclatasvir (DCV)±ribavirin (RBV) became the standard treatment in all National Committee for Control
Alaa Eldeen M Hashim, Samy Zaky, Magdy Z Alghannam, Sabry A Ibraheem, Fathiya M El-Raey, Ahmed Abdelaziz   +5 more
doaj   +1 more source

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj  

A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes

, 2016
Many direct-acting antiviral agents (DAAs) that selectively block hepatitis C virus (HCV) replication are currently under development. Among these agents is Daclatasvir, a first-in-class inhibitor targeting the NS5A viral protein. Although Daclatasvir is
Khaled H. Barakat (293854), Morris J. Robins (1651312), Anwar Anwar-Mohamed (1651315), Jack A. Tuszynski (160860), Michael Houghton (339213), D. Lorne Tyrrell (17808)   +5 more
core   +1 more source

Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients [PDF]

, 2018
Aim. To estimate efficacy and safety of direct antiviral drugs for hepatitis C treatment in donor lung recipients. Key points. The first cases in Russian literature and one of the first-ever cases of hepatitis C treatment by direct antiviral agents in ...
N. A. Mukhin, V. T. Ivashkin, D. T. Abdurakhmanov, Ye. . Sidorova, I. N. Tikhonov   +4 more
core   +1 more source

A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity.

PLoS Pathogens, 2014
Widely used chemical genetic screens have greatly facilitated the identification of many antiviral agents. However, the regions of interaction and inhibitory mechanisms of many therapeutic candidates have yet to be elucidated.
Hangfei Qi, C Anders Olson, Nicholas C Wu, Ruian Ke, Claude Loverdo, Virginia Chu, Shawna Truong, Roland Remenyi, Zugen Chen, Yushen Du, Sheng-Yao Su, Laith Q Al-Mawsawi, Ting-Ting Wu, Shu-Hua Chen, Chung-Yen Lin, Weidong Zhong, James O Lloyd-Smith, Ren Sun   +17 more
doaj   +1 more source

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection

, 2016
Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and white
Pyrsopoulos, Nikolaos, Jeffers, Lennox, George Kong, Morgan, Timothy R, Hughes, Eric, Luketic, Velimir, Paul J. Thuluvath, Natarajan Ravendhran, Maribel Rodriguez-Torres, Thuluvath, Paul J, Pearlman, Brian, Khallafi, Hicham, Steven-Huy Han, Rodriguez-Torres, Maribel, Eric Hughes, Lawitz, Eric, John M. Vierling, McPhee, Fiona, Velimir Luketic, Vierling, John M, Ghalib, Reem, Michelle Treitel, Treitel, Michelle, Kong, George, Christopher O’Brien, Rustgi, Vinod, Philip D. Yin, Bienvenido Yangco, Stephen Harrison, O'Brien, Christopher, Lennox Jeffers, Hicham Khallafi, Han, Steven-Huy, Timothy R. Morgan, Harrison, Stephen, Vinod Rustgi, Yin, Philip D, Eric Läwitz, Philippe J. Zamor, Zamor, Philippe J, Brian Pearlman, Fiona McPhee, Nikolaos Pyrsopoulos, Ravendhran, Natarajan, Reem Ghalib, Yangco, Bienvenido   +45 more
core   +1 more source

Avances en hepatitis C

Revista del Hospital Italiano de Buenos Aires
La hepatitis C es la principal causa de hepatitis crónica, cirrosis y cáncer de hígado, así como la indicación más común de trasplante hepático en la Argentina y muchos otros países.
Ezequiel Mauro, Sebastián Marciano, Omar Galdame, Adrián Gadano   +3 more
doaj  

STABILITY INDICATING HPLC METHOD DEVELOPMENT AND VALIDATION FOR DETERMINATION OF DACLATASVIR IN PURE AND TABLETS DOSAGE FORMS

, 2017
A sensitive, simple, selective and accurate HPLC method was developed and validated for analysis of antiviral drug Daclatasvir (BMS-790052, DCV) in pure form and in tablet dosage form in the presence of its degradation products.
Hanaa Saleh, Gamal H. Ragab, Mohammed A. Othman
core   +1 more source